SIRT3 in vitro activity assay

WY Wen Yang
KN Koji Nagasawa
CM Christian Münch
YX Yingjie Xu
KS Kyle Satterstrom
SJ Seungmin Jeong
SH Sebastian D Hayes
MJ Mark P. Jedrychowski
FV F. Sejal Vyas
EZ Elma Zaganjor
VG Virginia Guarani
AR Alison E. Ringel
SG Steven P. Gygi
JH J. Wade Harper
MH Marcia C. Haigis
request Request a Protocol
ask Ask a question
Favorite

Activity assays were performed as described previously (Hubbard and Sinclair, 2013). Briefly, 100μL reactions containing 0.5 μg purified SIRT3, 100 μM acetylated peptide (APVLFN-K(Ac)-EMIESM, Peptide 2.0), 150 μM NAD+ and 1.3 μg recombinant 6XHis-yPnc1 were incubated at 37° for 1 h in 1 mM DTT/PBS reaction buffer at either pH 6, 7 or 8. Negative control reactions lacking SIRT3 enzyme and positive control reactions containing 1.3 μg recombinant 6XHis-yPnc1 and 150 μM nicotinamide were performed in parallel. 100 μl OPT Developer Solution (10 mM ortho-pthalaldehdye (Sigma Aldrich), 10 mM DTT, 30% ethanol, 70% PBS, pH 7.4) was subsequently added to the reactions and incubated at room temperature for 1 h on an orbital shaker, protected from light. Fluorescence was read on a Varian Cary Eclipse fluorimeter at 420ex/460em wavelengths. Data was normalized to readings for the yPnc1 control reactions at each pH. All reactions were performed in triplicate.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A